FAIR VALUE - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended
	May 20, 2020	May 31, 2020	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration				$ 8,700,000		$ 0
Long-term contingent consideration				20,859,000		$ 168,000
Proceeds from sale of investments				6,000,000	$ 0
Collegium warrants
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Proceeds from sale of investments		$ 6,000,000.0
Investment, carrying value derecognized		$ 6,500,000
Loss on sale of investments				500,000
Collegium Pharmaceutical Inc | Receivables from Collegium
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, fair value price (in dollars per share)			$ 16.33
Collegium Pharmaceutical Inc | Receivables from Collegium
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, expected term			2 years 7 months 9 days
Warrant, risk-free rate			0.27%
Warrant, remaining contractual period			2 years 7 months 9 days
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration				8,700,000
Long-term contingent consideration				$ 20,700,000
INDOCIN | Zyla Life Sciences | Option Pricing Model
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, future royalties, estimated revenue, period	10 years
INDOCIN | Zyla Life Sciences | Discounted Cash Flow
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, future royalties, present value rate, percent	11.00%
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000.0